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Abstract
Background:  Small intestinal biopsy with villous atrophy (VA) is the gold standard for the
diagnosis of celiac disease (CD). We validated VA (Marsh 3) and small intestinal inflammation
without VA (Marsh 1+2) in Swedish regional biopsy registers.
Methods: All pathology departments in Sweden (n = 28) were searched to identify individuals with
VA or duodenal/jejunal inflammation. The validation consisted of blinded examination of biopsy
samples, manual review of biopsy reports, web surveys, and patient chart reviews of 121 individuals
with VA and 39 with inflammation.
Results: We identified 29,148 individuals with VA and 13,446 individuals with inflammation. In a
blinded examination, Swedish pathologists correctly classified 90% of biopsies with VA. Manual
screening of 1,534 biopsy reports (performed by co-author JFL and a research assistant) found that
comorbidity other than CD was rare. IBD was the most common comorbidity and occurred in
0.3% of biopsies with VA (1.6% in inflammation). Among 114 patients with VA and available data,
108 (95%) had a clinical diagnosis of CD. 79% of the validated individuals with VA and 64% of those
with inflammation had documented gastrointestinal symptoms prior to biopsy. 88% of the validated
individuals with VA had positive CD serology before their first biopsy. 172/180 (96%) of Swedish
gastroenterologists and 68/68 (100%) of pediatricians perform a small intestinal biopsy in at least 9
out of 10 individuals prior to diagnosis of CD.
Conclusion: Regional biopsy data are feasible to identify individuals with CD and small-intestinal
inflammation. The specificity of CD is high in villous atrophy.
Background
Small intestinal biopsy is the gold standard of celiac dis-
ease (CD) diagnosis [1]. In a patient with CD, the biopsy
typically shows villous atrophy (VA; Figure 1). Treatment
with a gluten-free diet should then lead to improvement
in symptoms and intestinal morphology on control
biopsy [2,3].
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We identified 29,148 individuals with VA and 13,446
individuals with small intestinal inflammation (called
"inflammation" in this paper) through a search of all
pathology departments of Sweden (n = 28).
The overall aim of the current study was to validate VA
and inflammation in small intestinal biopsies obtained
from Swedish biopsy registers and to evaluate if biopsy
registers can be used as a data source for CD and inflam-
mation. We specifically examined a) the accuracy of his-
topathological classification of small intestinal biopsies
by Swedish pathologists; b) the proportion of biopsy
reports with VA or inflammation where other disease than
CD is mentioned; c) to what extent VA corresponds to a
clinical diagnosis of CD; d) the characteristics (symptoms
and CD serology) of 160 validated individuals with VA or
inflammation; and e) the use of small-intestinal biopsy
among Swedish gastroenterologists and pediatricians to
diagnose CD.
Methods
Classification of biopsy data
Pathologists in Sweden, and elsewhere, will routinely
examine the presence (or absence) of VA, crypts, the dif-
ferent layers of the intestine, and the number of intraepi-
thelial lymphocytes (IELs) (Table 1) in small intestinal
biopsies. Finally, the pathologist examines the brush bor-
der for evidence of infection. In Sweden, all small intesti-
nal biopsies are classified according to the SnoMed system
for diagnostic and register purposes. SnoMed ("Systema-
tized Nomenclature of Medicine-Clinical Terms") is a
multilingual clinical healthcare terminology http://
Photographs of the small intestine: classifcation of histopathology Figure 1
Photographs of the small intestine: classifcation of histopathology. a. Normal mucosa. b. Inflammation (intraepithelial 
lymphocytosis). c. Partial VA (CD). d. Total VA (CD). (Acknowledgement. Photomicrographs obtained from Prof. Åke Öst, 
earlier chairman of the Swedish National Steering Group for Small Intestinal Pathology).BMC Gastroenterology 2009, 9:19 http://www.biomedcentral.com/1471-230X/9/19
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www.ihtsdo.org/our-standards/. In Sweden, SnoMed
codes are often complemented with a "KVAST/Alexander"
code" that is communicated to the physician who per-
formed the biopsy. From an international perspective, the
most common classification system of CD is the Marsh
system ("Marsh-Oberhuber") [4], although recently
Corazza et al suggested an alternative classification system
with improved degree of interobserver reproducibility [5].
Table 1 contains an overview of different histopathology
classifications and lists the SnoMed codes used in this
project to identify individuals with VA and inflammation.
In this project, inflammation is equivalent to Marsh 1+2
and VA equivalent to Marsh 3. Swedish SnoMed classifica-
tion does not allow distinction between Marsh 1 and
Marsh 2.
Collection of biopsy data
Biopsy data were collected through computerized
searches of all regional pathology departments in Sweden
(28 out of 28 departments). These departments also
included the private pathology department Medilab,
which is responsible for the examination of biopsy sam-
ples from many private pathologists, as well as samples
from the Gotland County. Medilab has also archived
biopsy results from former private pathologists who have
retired. Regional biopsy data in Sweden are primarily
archived in two different computer systems "Safir" and
"Sympathy". Local IT technicians were asked to perform
searches for appropriate morphology codes and then save
data on a) arrival date of the biopsy, b) Personal Identity
Number, c) morphology and d) topography (T64 = duo-
denum; T65 = jejunum). Computerized searches were
then exported to Microsoft Excel format and delivered to
the researchers. In total we received 189 Microsoft Excel
files from the 28 pathology departments. Each file was
examined by JFL and LB. On one occasion, the computer-
ized search was inadequate and had to be re-performed at
the regional pathology department. JFL and LB then col-
laborated on cleaning the data and identifying data irreg-
ularities. Biopsy data were finally merged into one file.
Initially we collected all small intestinal biopsy samples
(normal mucosa, inflammation and VA) and at the end of
the data collection, identified individuals with VA and
inflammation according to relevant SnoMed codes. Data
collection took place between the 27th of October 2006
and the 12th of February 2008.
Validation of VA and inflammation
The accuracy of histopathological classification of small intesti-
nal biopsies was surveyed in 1999, when the Swedish
National Steering Group for Small Intestinal Pathology
sent out small intestinal biopsy samples to 22 Swedish
pathology departments. Each biopsy sample had first
Table 1: Small intestinal histopathology classifications – a comparison
Classification used in this project Normal Inflammation Villous atrophy
Marsh Classification* Type 0 Type 1 Type 2 Type 3a Type 3b Type 3c
Marsh
Description
Pre-infitrative Infiltrative Infiltrative-hyperplastic Flat destructive
Corazza et al [5] - Grade A Grade B1 Grade B2
SnoMed Codes M0010,
M0011
M40000, M41000,
M42000, M43000,
M47000, M47170
M58,
D6218,
M58005
M58,
D6218,
M58006
M58,
D6218,
M58007
KVAST/Alexander classification I
Normal
II
Intraepithelial lymphocytosis (IEL)#
III
Partial VA
IV
Subtotal VA
IV
Total VA
Characteristics
Villous atrophy - - - + ++ ++
IEL# - + + + + +
Crypt hyperplasia - - + + ++ ++
*We have not included Marsh type 4 in this classification since such lesions are very rare [9] and cannot be identified through SnoMed Codes.
# Increased intraepithelial lymphocyte count (often >30/100 epithelial cells).BMC Gastroenterology 2009, 9:19 http://www.biomedcentral.com/1471-230X/9/19
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been categorized through consensus of the steering group
(gold standard) and was then graded by blinded patholo-
gists from the 22 pathology departments. This validation
(distribution of biopsy samples and collection of results)
was coordinated by the non-profit company Equalis http:/
/www.equalis.se/. Data on the accuracy were obtained
from Equalis and compiled by JFL.
We evaluated the specificity of VA and inflammation. We
did so by estimating the proportion of biopsy reports (with VA
or inflammation) where other disease than CD was mentioned.
In total we had data on 56,176 unique biopsies (VA:
38,655; inflammation: 17,521) in 29,148 individuals
with CD and 13,446 individuals with inflammation. A
computerized search of the plain text of these biopsy
reports yielded 1,534 biopsy reports where there were
indications of comorbidity other than CD. Each of these
biopsy reports (n = 1,534) was then manually screened by
two independent reviewers (JFL and research assistant) to
confirm or reject the presence of comorbidity. Discrepan-
cies were resolved through a third review of the biopsy
report in question.
The manual review of biopsy reports was then comple-
mented with a review of patient charts from 160 individuals
undergoing small intestinal biopsy (121 with VA and 39
with inflammation). These individuals were randomly
selected from five counties contributing biopsy data
(these counties in total supplied 5,317 individuals with
VA and 2,215 with inflammation). These 160 validated
individuals had been referred for biopsy from 45 different
clinics or health care centers. We specifically looked at the
clinical characteristics of patients with VA and inflamma-
tion and dietary treatment and dietary compliance in indi-
viduals with VA. We were able to characterize 118
individuals with VA and 39 individuals with inflamma-
tion with regards to clinical symptoms and laboratory
measures. There were patient chart data on dietary com-
pliance in 71–101 individuals with VA. Finally we
obtained all available CD serology data on the 160 vali-
dated individuals described above in order to correlate
CD serology with VA.
We also examined the clinical management of CD in Swe-
den. This included the use of small intestinal biopsy prior
to diagnosis of CD, the histopathological examination of
small intestinal biopsies by pathologists and the treat-
ment of CD. For this purpose we carried out three web sur-
veys. Potential survey respondents were identified
through member registers, email lists and through the
Swedish Association of Pathology.
To identify (adult) gastroenterologists, we matched the
member register of the Swedish Gastroenterology associa-
tion with the administrative register of Swedish physicians
http://www.hsar.se/ and identified 282 active gastroenter-
ologists with a postal address in Sweden and an e-mail
address. These individuals were then sent information by
post and email about a survey on CD in adults, as well as
the web address of an 11-item-survey. The results of this
survey have previously been published in a Swedish-lan-
guage journal (Gastrokuriren).
We identified pediatricians with an interest in gastroenter-
ology through two existing e-mail lists for Swedish pedia-
tricians (one for CD and one for general pediatric
gastroenterology, including IBD). 70 pediatricians were
then emailed information about a survey on CD in chil-
dren, as well as the web address of a pediatric 11-item-sur-
vey. The results of this survey have previously been
published in a Swedish-language journal (Barnläkaren).
After permission from the Swedish-language journals Gas-
trokuriren and Barnläkaren, we included data on CD inves-
tigation and management in this paper[6,7], since these
Swedish journals are not indexed by Medline (or any
other medical database) and contain no English-language
abstract. Written permissions from Gastrokuriren  and
Barnläkaren have been separately uploaded to BMC Gas-
troenterology.
To define the histopathological examination of small
intestinal biopsies, we emailed 25 pathology departments
and asked them to answer an 18-item-survey. Although,
28 pathology departments contributed data to our study,
3 smaller pathology departments participating in our
study formally had the same head pathologist as the uni-
versity hospital of their health care region and referred us
to the larger department for our survey.
Statistics
We calculated 95% confidence intervals (CI).
Ethics
The current study was performed as part of a larger project
on complications in CD and inflammation. That study
was approved by the Regional Ethical Review Board in
Stockholm on the 4th of June 2006 (2006/633-31/4) with
additional amendments (2007/747-32 and 2008/257-
32).
For the validation of the 160 patients, we obtained spe-
cific permission from the National Board of Health and
Welfare.
Results
We identified 381,043 small intestinal biopsies. Of these,
28,654 were duplicates (biopsies could be identified more
than once if histopathology SnoMed codes indicated both
inflammation and villous atrophy). Of the remainingBMC Gastroenterology 2009, 9:19 http://www.biomedcentral.com/1471-230X/9/19
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352,389 biopsies we excluded 986 due to data inconsist-
encies (including incorrect Personal Identity Number).
The final 351,403 small intestinal biopsies, from which
we identified individuals with VA and inflammation, rep-
resented 287,586 unique individuals. 240,922 individu-
als had only one small intestinal biopsy. Less than 1% had
been biopsied on more than three occasions.
We identified 29,148 unique individuals with VA at some
stage and 13,446 unique individuals with inflammation
at some stage but never VA. The median year of biopsy
with VA or inflammation was 1998, ranging from 1969–
2008 in individuals with VA to 1970–2008 in individuals
with inflammation. Except for the above description of
the biopsy data collection, all data in this paper refer only
to individuals with VA or inflammation.
Age and sex of individuals with a small intestinal biopsy
The majority of study participants were females; and
adults predominated at first biopsy (Table 2). In individ-
uals with VA 36.8% were children (≤ 15 years) at first pos-
itive biopsy, compared with 6.1% of those with
inflammation.
Validation of VA and inflammation
Blinded classification of small intestinal biopsies
Ninety percent (90%; 95% CI = 87–94%) of biopsies with
VA were correctly classified as defined by the National
Steering Group of Small Intestinal Pathology (Table 3).
The proportions of missing data were independent of the
grading of the biopsy. Fifty-six percent (41–72%) of biop-
sies with inflammation were correctly classified.
Manual examination of biopsy reports
Our examination of 1,534 biopsy reports, found that
small intestinal pathology other than CD, as mentioned
in the biopsy report, was uncommon in VA or inflamma-
tion (Table 4). The most common comorbidity was IBD,
occurring in 0.3% (0.2–0.3%) of biopsies with VA and
1.6% (1.4–1.7%) of biopsies with inflammation (see
Additional File 1.
CD among individuals with VA
According to patient chart data, VA had a high specificity
for CD. 108 (95%; 91–99%) out of 114 patients with VA
and available data had a clinical diagnosis of CD (Figure
2) [8]. In seven individuals (121 minus 114), the CD diag-
nosis could neither be confirmed, nor rejected (Figure 2).
This was due to emigration, inconsistent SnoMed coding
etc. In individuals where the diagnosis was rejected (n =
6), four biopsies (patients 1–4) had been misclassified in
the relevant department of pathology. Patient 5 had VA,
but received gluten-containing food after the diagnostic
biopsy. A second upper endoscopy 18 years later found
that patient 5 had a normal mucosa and the CD diagnosis
was re-evaluated. In patient 6, a biopsy initially classified
as "VA" was later re-examined (on request from the physi-
cian) and then found not to fulfill the criteria for VA (or
CD).
Clinical characteristics of individuals with VA and inflammation
Clinical characteristics of the reviewed individuals are pre-
sented in Table 5. Most individuals presented with classi-
cal features, with diarrhea being the most common
symptom in individuals with VA. Although, 64% (49–
79%) of individuals with inflammation had some gas-
trointestinal symptom prior to biopsy, the single most
common symptom/sign was anemia (31%; 16–45%).
Folic acid deficiency was reported in 22% (15–30%) of
individuals with VA, but only in 5% (1–17%) of individ-
uals with inflammation.
93% of individuals with VA (94/101; 88–98%) had
received dietary information according to patient chart
data. There were indications of low dietary compliance
(not strict gluten-free diet) in 15/86 individuals with VA
(17%; 9–25%). Five out of 71 patients (7%; 1–13%) did
not respond satisfactorily to a gluten-free diet. Two of the
patients with little response to a gluten-free diet however
admitted low dietary compliance.
Two individuals (5%; 1–17%) with inflammation (and
who had never had VA) had at some stage received infor-
mation about gluten-free diet. None of these individuals
had however received a clinical diagnosis of CD according
to the patient chart.
Table 2: Characteristics of unique individuals at first positive 
small intestinal biopsy
VA Inflammation
Number 29,148 13,446
Age, yrs (median, range) 30; 0–102 48; 0–104
Children ≤ 15 years (%) 10,718 (36.8)* 821 (6.1)#
Children ≤ 21 years (%) 12,273 (42.1) 1,515 (11.3)
Females (%) 18,033 (61.9) 7,575 (56.3)
Entry year (median, range) 1998; 1969–2008 1998; 1970–2008
*Only includes biopsies with villous atrophy. 46 individuals with their 
first "positive biopsy" (characterized by villous atrophy) after the age 
of 15 years had had a biopsy without VA when aged ≤ 15 years. 
Including them, the proportion of individuals with villous atrophy 
having "any small intestinal biopsy" ≤ 15 years of age was 36.9%.
#Only includes biopsies with inflammation. 24 individuals with their 
first "positive biopsy" (characterized by inflammation without villous 
atrophy) after the age of 15 years had had a normal biopsy when aged 
≤ 15 years. Including them, the proportion of individuals with 
inflammation having "any small intestinal biopsy" ≤ 15 years of age was 
6.3%.BMC Gastroenterology 2009, 9:19 http://www.biomedcentral.com/1471-230X/9/19
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In 71 (88%; 80–95%) out of 81 individuals with VA and
available CD serology data, there was at least one positive
antibody test (gliadin, endomysium or transglutaminase)
prior to first biopsy (Table 6). After biopsy, most serology
samples in the validated individuals with VA were nega-
tive (Table 6). Among 39 individuals with inflammation
(and no VA), two (5%; 1–17%) had a positive CD serol-
ogy prior to biopsy (none of them received a clinical diag-
nosis of CD according to patient charts).
Clinical management of CD
Our web surveys found that most gastroenterologists and
pediatricians biopsy their patients prior to CD diagnosis
and that almost all patients with CD receive information
about gluten free diet.
Among 282 available gastroenterologists, 184 (65%) gas-
troenterologists participated in our survey. 96% (91–
98%) of Swedish gastroenterologists perform a small
intestinal biopsy in at least 9 out of 10 patients prior to
diagnosis of CD (Table 7). 93% (89–97%) inform at least
9 out of 10 patients with CD about gluten-free diet.
68 pediatricians (97% of those contacted) participated in
our survey (Table 8). 100% (95–100%) of the pediatri-
cians perform a small intestinal biopsy in at least 9 out of
10 patients prior to diagnosis of CD. 97% (90–100%)
inform at least 9 out of 10 patients with CD about gluten-
free diet.
Survey of pathology departments: evaluation of CD and 
inflammation
Among 25 contacted departments of pathology, 23 (92%)
responded to our histopathology survey. 20/23 (87%;
73–100%) pathology departments use a Swedish his-
topathological classification system called "KVAST/Alex-
ander", with 3 departments using the Marsh classification
when they communicate pathology findings to the physi-
cian (Table 1). All pathology departments however also
classify biopsy samples according to the international
SnoMed classification system http://www.snomed.org/.
20/23 (87%; 73–100%) pathology departments reported
that most pediatricians and gastroenterologists would
send 2–3 tissue samples from the duodenum/jejunum
(originating from one endoscopy session) for referral (1
(4%) reported that most gastroenterologist would send
only 1 biopsy samples for microscopic examination;
while 2 departments (9%) reported 4 or more samples to
be routine). 19/23 (83%; 67–98%) pathology depart-
ments said that their histopathology report would be
based on the most severe finding at microscopic examina-
tion, while 4 (17%) reported that the most common find-
ing would form the basis of their pathology report. When
asked what (minimum) villous-crypt ratio would be
accepted as normal, 3:1 was used in most departments
(18/23; 78%; 64–95%) (all other departments reported a
4:1 (13%) or a 2:1 (9%) ratio to be accepted as normal).
None of the pathology departments requested a 5:1 ratio.
22/22 (100%; 85–100%) pathology departments used
immunostaining for CD3 to detect IELs. 19/23 (83%; 67–
98%) reported using 30 IELs per 100 as their cut-off for
"increased IEL count", while 1 department reported using
25 and 3 departments used 20 as their cut-off. Other
results of this survey are presented in Table 9.
Discussion
This paper describes the validation of VA and inflamma-
tion in small intestinal biopsies from the 28 pathology
departments in Sweden. In Sweden, pathologists have tra-
ditionally divided CD-like lesions into a) VA and b)
inflammation without VA, with further subdivisions into
partial, subtotal and total VA. Inflammation (Table 1) cor-
responds to both Marsh 1 and Marsh 2 and grade A in the
newly introduced classification by Corazza et al [5]. This
means that Swedish biopsy registers do not distinguish
between Marsh 1 and Marsh 2.
We identified 29,148 individuals with VA and 13,446
individuals with inflammation through computerized
searches of all pathology departments in Sweden. In our
validation, VA had a high specificity for CD, which is not
surprising since other causes of VA than CD are rare in
Table 3: Accuracy of histopathological classification
Samples mailed
to pathologists
Not
Responding
Correctly
classified
Worst case
Scenario#
Normal* 84 7 (8%) 74/77 (96%) 74/84 (88%)
Inflammation* 42 3 (7%) 22/39 (56%)§ 22/42 (52%)
Villous atrophy* 231 21 (9%) 190/210 (90%) 190/231 (82%)
* According to gold standard (= grading by the Swedish National Steering Group for Small Intestinal Pathology).
# Assuming that all missing responses were incorrect.
§ Of the misclassified 17 samples with inflammation (according to the steering group, i.e. gold standard), 12 were classified as normal, and 5 as 
villous atrophy.BMC Gastroenterology 2009, 9:19 http://www.biomedcentral.com/1471-230X/9/19
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Western countries [9]. In our manual review of more than
1,500 biopsy reports, comorbidity such as IBD, giardiasis,
helicobacter pylori-infection, gastric metaplasia or cancer
was rare in VA or small intestinal inflammation (Table 4)
(also for biopsy samples with inflammation, was other
co-morbidity than CD uncommon. In "inflammation",
IBD accounted for 1.6% of biopsies with small-intestinal
inflammation). Our patient chart review found that 95%
of biopsy reports with VA were consistent with clinical
CD. Although, VA may be patchy and biopsy samples
without atrophy may be misinterpreted as atrophic by the
pathologist if the samples are wrongly oriented, earlier
validation has shown that the vast majority (90%) of
intestinal biopsies with VA are correctly classified by
Swedish pathologists (Table 3). Although, not all pathol-
ogists responded to this survey (Table 3), missing
responses were equally distributed between biopsies with
normal mucosa, inflammation and VA. This suggests that
missing responses were not biased towards biopsy sam-
ples that are difficult to evaluate since we then would have
expected a higher rate of missing values in samples with
inflammation. Pathologists also reported that almost 9
out of 10 pediatricians/gastroenterologists submit at least
two biopsy samples from the small intestine (instead of
just one sample) when CD is investigated. Multiple sam-
ples increase the likelihood of identifying VA. We con-
clude that biopsy data with VA may be used as a data
source for CD, although comorbidity may be underesti-
mated when evaluated from biopsy reports since not all
comorbidity is mentioned in biopsy reports.
Unfortunately we did not have access to the referral notes
from the physician. Such notes often contain additional
clinical information about the reason for biopsy. With
access to referral note data it is possible that we could have
Table 4: Comorbidity in biopsy samples – results of manual 
examinations of 1,534 biopsy reports
Histopathology Villous Atrophy Inflammation
Samples, No. 38,655 (%*) 17,521 (%*)
Autoimmune enteropathy 10 21 (0.1)
Gastric metaplasia 37 186 (1.1)
Giardiasis 5 2
Helicobacter pylori 73 (0.2) 70 (0.4)
Inflammatory granuloma 14 41 (0.2)
Lymphoma 13 7
Cancer other than lymphoma 29 51 (0.3)
Tropical sprue 1 0
Crohn's disease 21 94 (0.5)
Colitis: Microscopic/Ulcerative 73 (0.2) 163 (0.9)
Any IBD# 98 (0.3) 272 (1.6)
Postoperative changes 17 60 (0.3)
Vasculitis 1 0
Refractory CD 3 0
We also searched plain biopsy text for immune deficiency, Behcet's 
disease, graft vs. host disease/transplantation, sarcoidosis, 
immunoglobuline disease, Systemic Lupus Erythematosus, Whipple's 
disease and Zollinger-Ellison Disease. For these disorders, the 
computerized search only yielded results that were rejected on 
manual examination.
*Percentages are listed where the prevalence is 0.1% or more.
#Includes biopsy reports where non-specific IBD was listed.
IBD = Inflammatory bowel disease
Overview of patient chart review Figure 2
Overview of patient chart review. 95% of all individuals 
with VA had a clinical diagnosis of CD according to the 
patient charts (95% CI = 91–99%). This is consistent with 
data from an earlier Swedish study showing that out of 524 
children with a positive first biopsy, 509 improved in their 
mucosa when starting on a gluten-free diet (corresponds to 
97.1%)[8]. *Other sources: In two patients, we phoned the 
responsible physician and the diagnosis of CD could then be 
confirmed. In a third patient, no patient chart could be 
obtained. However, through the local chemistry laboratory, 
we obtained data on CD serology that showed positive 
endomysium and antigliadin antibodies prior to biopsy, and 
negative endomysium and antigliadin antibodies after biopsy. 
Also this patient was regarded as having CD.
Patient data through other sources*
N=3
Celiac Disease
N=108 (95%)
Pathology department error
N=4
Other diagnosis than Celiac Disease  .
N=2
No Celiac Disease (rejected)
N=6
Evaluated
N=114
CD diagnosis -
not confirmed/not rejected
N=7
Patient chart data
N=118
Villous atrophy
N=121BMC Gastroenterology 2009, 9:19 http://www.biomedcentral.com/1471-230X/9/19
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Table 5: Clinical characteristics of individuals with VA and inflammation – patient chart review.
Villous atrophy;
N = 118
Inflammation;
N = 39
Background data
Females 72 (61) 16 (41)
Median age at first biopsy; range (years) 42; 1–86 53; 1–84
Median follow-up; range (years) 7; 0–24 6; 0–17
Heredity
Reported heredity for CD 14 (12) 2 (5)
Reported heredity for type 1 diabetes 3 (3) 0 (0)
Other diseases
Diabetes Mellitus, type 1 5 (4) 1 (3)
Dermatitis herpetiformis 6 (5) 0 (0)
Other autoimmune disease 11 (9) 8 (21)
Symptoms
Any gastrointestinal symptom* 93 (79) 25 (64)
Diarrhea 42 (36) 7 (18)
Anemia 41 (35) 12 (31)
Weight loss/growth failure 34 (29) 3 (8)
Abdominal pain 22 (19) 9 (23)
Vomiting or nausea 15 (13) 6 (15)
Constipation 12 (10) 1 (3)
Fatigue 9 (8) 3 (8)
Laboratory data
Iron-deficiency 32 (27) 5 (13)
Folic acid deficiency 26 (22) 2 (5)
B12-deficiency 16 (14) 1 (3)
Thrombocytes, increased 15 (13) 4 (10)
Low albumin 12 (10) 7 (18)
Erythrocyte sedimentation rate, increased 9 (8) 3 (8)BMC Gastroenterology 2009, 9:19 http://www.biomedcentral.com/1471-230X/9/19
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distinguished individuals with inflammation biopsied
due to suspected CD from those biopsied due to other
cause such as IBD. To some extent this can be done
through manual screening of the running biopsy text, but
it is still likely that inflammation in Swedish biopsy regis-
ters is a heterogeneous concept representing both CD and
other diseases.
The sensitivity of diagnosed CD should be close to 100%
through biopsy registers, since a duodenal/jejunal biopsy
with VA is gold standard for CD diagnosis in Sweden
[10,11] (see also Tables 7 and 8). However, although data
on CD management were obtained from almost all pedi-
atricians surveyed, our response rate was lower among
gastroenterologists investigating and treating adults
(65%). This response rate is similar to that in a review by
Asch et al (usually 5–6 out of 10 physicians respond to
mailed surveys) [12]. Nevertheless, there is a risk of selec-
tion bias and we cannot exclude that our respondents
were more interested in CD than the average Swedish gas-
troenterologist and that this influenced the results of our
survey.
Until now, most large Swedish cohort studies of CD have
used the Swedish National Hospital Discharge Register to
identify patents with CD (e.g. [13-16]). Regional biopsy
registers do however offer several advantages over the
Hospital Discharge Register when it comes to identifying
CD (and inflammation). Foremost among these advan-
tages may be higher specificity and sensitivity for both CD
and inflammation.
While the Swedish Hospital Discharge Register and other
diagnostic registers, cannot be used to identify inflamma-
tion, biopsy registers constitute a means to identify tissue-
verified inflammation. Data from the Swedish National
Steering Group for Small Intestinal Pathology show that
56% of biopsy samples with inflammation are correctly
classified. This is lower than for VA but may still be higher
than when using the traditional Marsh classification sys-
tem. Our data are in fact similar to those reported by Ital-
ian researchers using a simplified Marsh classification
system [5]. The Italian researchers had earlier noted that
the interobserver reproducibility was lower for Marsh 1
and Marsh 2 (especially for Marsh 2) [5] than for Marsh 3
(especially Marsh 3c). However, partial Kappa scores
increased significantly when they merged Marsh 1 and
Marsh 2 lesions into what they call "grade A". This con-
cept (Grade A) is actually identical to "small intestinal
inflammation" in Swedish biopsy registers. The tradi-
tional use of grading small intestinal inflammation into
VA vs. inflammation (without VA) stems from the long-
term use of VA as the basis of CD diagnosis in Sweden [2]
Increasingly it has however been recognized that CD may
be present in the absence of VA and that additional meas-
ures including genetic and immunological markers may
be important in the investigation of CD ([17]. The current
study had no data on either genetic or immunological
Liver enzymes, increased 9 (8) 4 (10)
Biopsy report
Original biopsy report could be examined through
patient chart reviews
98 (83) 33 (85)
Clinical data (about the patient) is described in the
biopsy referral letter (to the pathologist)#
90 (92) 28 (85)
Macroscopic appearance of the intestine is described
in the referral letter#
39 (40) 14 (42)
Percentages are given within brackets. Although, the diagnosis CD was evaluated in 121 individuals, patient chart data were only available in 118 
(98%).
*Weight loss was included among "any GI symptom". Also reflux symptoms (not listed above) were included among "any GI symptoms".
#Based on 98 and 33 biopsy reports respectively.
Table 5: Clinical characteristics of individuals with VA and inflammation – patient chart review. (Continued)
Table 6: CD serology before and after first biopsy in individuals with VA
Positive serology before biopsy (%) Negative serology after biopsy (%)
Gliadin Endomysium Transglutam. Gliadin Endomysium Transglutam.
39/53 (74) 46/56 (82) 28/33 (85) 54/60 (90) 31/36 (87) 29/35 (83)BMC Gastroenterology 2009, 9:19 http://www.biomedcentral.com/1471-230X/9/19
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markers. Previous research suggests that up to 40% of
individuals with inflammation (as defined by increased
IEL count) may suffer from gluten sensitive enteropathy
[18], but as noted earlier our histopathology approach
does not distinguish between CD-inflammation and non-
CD-inflammation.
Another weakness of our methodological approach is that
we have no data on the exact numbers and distribution of
IELs in biopsies with inflammation. It has been suggested
that a uniform distribution of IELs is increases the propor-
tion of CD in patients with inflammation without VA
[19]. The lack of exact number and distribution of IELs in
biopsies with inflammation is a limitation of our study.
"Positive biopsy" for VA has been the recommended gold
standard for CD for the last 30–40 years[2,20]. In con-
trast, CD serology has only been generally available in
Sweden since the mid-1990s. This means that using
biopsy registers to identify individuals with CD allows for
substantially longer follow-up of patients than if using
CD serology data to identify patients with CD. Even
though the sensitivity of e.g. tissue transglutaminase
autoantibodies is high in total VA, it decreases to around
70% in partial VA (also CD) and is even lower in inflam-
mation [21]. CD serology has a high specificity [22] for CD
and a high negative predictive value. CD serology is there-
fore well suited to rule out the presence of CD. In contrast,
the positive predictive value of CD serology has been dis-
appointing, which is not surprising given that 99% of all
Westerners do not  have CD [23,24] (only a minute
decrease in specificity will then result in false-positive
cases). In two recent papers, the positive predictive value
of tissue transglutaminase antibodies varied between 29–
76%[25,26]. For the above reasons we chose to identify
CD and inflammation through biopsy reports instead of
serological data.
Table 7: Management of CD among gastroenterologists
Topic ≥ 9 out of 10 patients 5–8/10 patients 1–4/10 patients No patient/
never
Total*
Biopsy performed prior to CD diagnosis 172 (96) 7 (4) 0 (0) 1 (0.6) 180
Control biopsy performed to verify mucosal healing on 
gluten-free diet
64 (36) 29 (16) 57 (32) 30 (17) 180
Gluten provocation and third biopsy performed 1 (0.6) 1 (0.6) 16 (9) 161 (90) 179
CD serology is part of "my diagnostic algorithm for CD" 141 (78) 14 (8) 19 (11) 6 (3) 180
"My patients with CD" receive information about gluten-
free diet by health-care personnel
164 (93) 1 (0.6) 4 (2) 7 (4) 176
*Number of respondents (percentages within brackets were calculated based on these numbers).
Table 7 has previously been published in the Swedish-language journal Gastrokuriren [6,7], and is re-published after permission from that journal.
Table 8: Management of CD among pediatricians
Topic ≥ 9 out of 10 patients 5–8/10 patients 1–4/10 patients No patient/never Total*
Biopsy performed prior to CD diagnosis 68 (100) 0 (0) 0 (0) 0 (0) 68
Control biopsy to verify mucosal healing on gluten-
free diet
9 (14) 3 (5) 36 (55) 18 (27) 66
Gluten provocation and third biopsy performed 0 (0) 0 (0) 38 (59) 26 (41) 64
CD serology is part of "my diagnostic algorithm for 
CD"
68 (100) 0 (0) 0 (0) 0 (0) 68
"My patients with CD" receive information about 
gluten-free diet by health-care personnel
65 (97) 0 (0) 0 (0) 2 (3) 67
*Number of respondents (percentages within brackets were calculated based on these numbers).
Table 8 has previously been published in the Swedish-language journal Barnläkaren [6,7], and is re-published after permission from that journal.BMC Gastroenterology 2009, 9:19 http://www.biomedcentral.com/1471-230X/9/19
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Symptoms and signs vary in CD [27-29]. "Classical CD"
presents with chronic diarrhea, abdominal pain, other
gastrointestinal symptoms and weight loss/growth retar-
dation [30] and is still common in children [27]. Increas-
ingly however, CD is detected in children with non-classic
symptoms, or through screening of first-degree relatives
and high-risk individuals (e.g. those with type 1 diabetes)
[31]). In adults, diarrhea is probably the dominating
symptom (i.e. the classic form), although silent CD [30] is
also common [32]. One of the limitations of biopsy regis-
ters, is that they contain no data on symptoms. We there-
fore characterized 121 patients with VA and 39 patients
with inflammation through patient chart reviews and col-
lection of CD serology data. Most of our patients with VA
presented with classical symptoms (diarrhea was the most
common symptoms). One in three patients with VA and
inflammation suffered from anemia at time of biopsy.
Our data on anemia and diarrhea in VA are thereby con-
sistent with earlier findings in CD[27,30,33]. Heredity for
CD was found in 12% of individuals with VA and in 5%
of individuals with inflammation. Although, we do not
know of any study examining the heredity for CD in indi-
viduals with inflammation without VA, Dube et al [24]
recently compiled data on CD heredity, with a pooled
prevalence of biopsy-verified CD of 16% among first-
degree relatives to CD patients. It is also noteworthy that
88% of the 81 validated patients with available CD serol-
ogy data and VA in our study had at least one positive CD
serological marker prior to first biopsy. Although, most
patients with VA had negative CD serology after first
biopsy, not all did. Positive serology after biopsy may be
explained by a number of factors including low compli-
ance, serology performed only shortly after biopsy, or
being performed at time of gluten provocation. In addi-
tion, a number of patients with VA may have persistently
abnormal CD serology despite gluten-free diet.
Among patients with VA and available data, we also char-
acterized dietary compliance. This review found indica-
tions of low dietary compliance in 17% of individuals
with VA. This is consistent with earlier data [34-37],
although it should be remembered that our data on die-
tary compliance were retrospectively collected through
patient charts. Another weakness of our data on dietary
compliance is that the follow-up differed between
patients, as did the time between CD diagnosis and eval-
uation of dietary compliance. Finally, there is a risk that
the basis of compliance assessment differed between phy-
sicians and dieticians; and that patients without informa-
tion on dietary compliance differ from those with such
information. Only 2/39 validated patients with inflam-
mation in our study had received information about glu-
ten-free diet and none of them had received a clinical
diagnosis of CD by their physician. This is not surprising,
given that Swedish patients with small-intestinal inflam-
mation by tradition do not receive a gluten-free diet.
Conclusion
In conclusion, we merged data from all 28 pathology
departments in Sweden and identified 29,148 individuals
with VA and 13,446 individuals with small-intestinal
inflammation. Our validation shows that it is feasible to
identify individuals with CD and small-intestinal inflam-
mation using regional biopsy data. The specificity of CD
is high in villous atrophy.
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Table 9: Management of CD in pathology departments (%)
Topic ≥ 9 out of 10 patients 5–8/10 patients 1–4/10 patients No patients/never Total*
The referral note from the physician contains 
clinical information
18 (78) 4 (17) 1 (4) 0 (0) 23
The referral note from the physician contains data 
on macroscopic appearance of the small intestine
7 (30) 8 (34) 6 (26) 2 (9) 23
Suppose that a pathologist is uncertain of the 
grading of a small intestinal biopsy samples. How 
often will he/she ask for a second opinion?
5 (23) 5 (23) 8 (36) 4 (18) 22
* Number of respondents (percentages within brackets were calculated based on these numbers).BMC Gastroenterology 2009, 9:19 http://www.biomedcentral.com/1471-230X/9/19
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